Tysabri Production Continues Ahead Of Possible Reintroduction
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec is manufacturing Tysabri at a slower rate since marketing of the MS therapy was suspended in late February, CEO Mullen says. Continued manufacturing is "prudent at this point," the firm says. Production pause provides an opportunity to enhance manufacturing facilities and processes.
You may also be interested in...
FDA Repeats Birth-Defect Risk With Roche, Novartis Transplant Drugs
PML could be a hazard, too, agency says.
FDA Repeats Birth-Defect Risk With Roche, Novartis Transplant Drugs
PML could be a hazard, too, agency says.
Biogen Idec Adds Liver Warning To Multiple Sclerosis Therapy Avonex
Interferon beta product joins Serono/Pfizer's Rebif with warning reflecting postmarketing experiences. Berlex' Betaseron does not have a warning but recommends testing. Coming on the heels of the Tysabri withdrawal, the labeling change is the second recent setback for Biogen Idec's multiple sclerosis franchise.